Applications of N-(2-Cyanoethyl)Glycine in Industrial Manufacturing

N-(2-Cyanoethyl)glycine serves as a specialty intermediate in several precision-driven sectors, supporting downstream product quality through its performance consistency, purity, and defined molecular characteristics. As a manufacturer, we ensure specification accuracy and traceability for each application below based on established industrial practice and regulatory compliance demands.

1. Pharmaceutical Intermediates for Peptide Synthesis

This raw material enters industrial-scale peptide synthesis processes, particularly for manufacturing non-standard amino acid residues frequently incorporated into pharmaceutical active ingredients. Downstream users integrate it during solid-phase peptide assembly to introduce cyanoethyl-protected glycine units, forming the backbone for modified peptide drugs targeting specific biological activity or improved PK profiles. Its controlled reactivity and high batch-to-batch purity minimize side products, supporting reproducibility mandated for large-scale API suppliers.

Industry compliance standards

• ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients)
• United States Pharmacopeia (USP) General Chapter <795>, if for compounding ingredients
• European Pharmacopoeia (Ph. Eur.), where applicable for amino acid derivatives
• ISO 9001:2015 Quality Management Systems in supply chain

Typical usage ratio

• Used at 1–8 mol% relative to total amino acid content, adjusted for peptide chain length and target modification density
• Optimization based on target peptide design and downstream cleavage strategy

Downstream process integration

• Dosed during the resin loading or coupling cycle in automated or manual peptide synthesizers
• Deprotection and global cleavage after sequence assembly, often using TFA-based protocols
• QC purification via preparative HPLC to isolate desired peptide with cyanoethyl modification

Final product types

• Modified oligopeptides and therapeutic peptides
• Specialty pharma intermediates for peptide conjugate drugs
• Synthetic vaccine antigens containing non-proteinogenic residues

2. Building Block for Oligonucleotide API Production

Industrial oligonucleotide synthesis has adopted this compound for introducing glycine spacers endowed with cyanoethyl protective groups into oligonucleotide APIs. It enters phosphoramidite-based automated synthesis lines, providing the flexibility for site-specific incorporation—key for next-generation antisense oligos and siRNA drugs. Quality control integrity, especially regarding residual cyanoethyl contaminants, is enforced throughout the supply chain for these applications.

Industry compliance standards

• US FDA cGMP for Oligonucleotide Drugs (21 CFR Parts 210, 211)
• ICH Q11 (Development and Manufacture of Drug Substances)
• Japanese Pharmacopeia, as applicable for oligonucleotide APIs
• ISO 13485 if ingredients used in medical device combinations

Typical usage ratio

• Typically 0.5–3.0 mmol per oligonucleotide synthesis batch, variable based on target backbone architecture
• Exact incorporation frequency depends on sequence length and design specifications

Downstream process integration

• Integrated into solid-phase automated synthesizer cycles as a protected monomer unit
• Removal of cyanoethyl group via base treatment during deprotection and cleavage steps
• HPLC or cartridge purification to exclude deletion or failure sequences

Final product types

• Antisense oligonucleotide APIs and siRNA therapeutics
• Molecular diagnostic probes containing non-natural linkers
• Modified aptamers for targeted drug delivery

3. Intermediate for Specialty Polymer Modification

In the advanced materials sector, formulators incorporate this compound as a functional modifier into specialty polymers needing improved chemical reactivity or tunable surface properties. Specifically, its unique cyano and amine functionalities act as grafting points on resin chains, lending downstream polymers new reactivity or crosslinking capacity demanded in high-mobility films and selected ion-exchange applications. Strict raw material traceability and performance testing at multiple production stages are standard procedure.

Industry compliance standards

• REACH Regulation (EC) No 1907/2006 (Europe) for chemical use in polymers
• TSCA Inventory Listing (USA) for polymer precursors
• ISO 14001 Environmental Management for responsible manufacturing
• Internal company specifications for film purity or ion-exchange grade, if for sensitive uses

Typical usage ratio

• Formulators typically add 0.1–2.5 wt% to the monomer feed, depending on target polymer architecture
• Dose refinement based on FTIR or GPC analysis post-synthesis

Downstream process integration

• Feeds directly into polymerization reactors as a co-monomer or chain-end modifier
• Crosslinking or curing steps leverage the introduced functionalities
• Films or beads cast, extruded, or granulated per final application

Final product types

• High-performance polymer films for electronics and membrane filtration
• Ion-exchange resins with tailored selectivity
• Functional bead polymers for chromatographic applications

4. Starting Material for Agrochemical Intermediate Synthesis

Selected agrochemical manufacturing pathways utilize this raw material as an early-stage intermediate for constructing bioactive molecules with glycine-derived linkers. Hydrogenation and derivatization steps convert the starting compound into functional moieties embedded in pesticides and herbicides engineered for targeted crop protection. Process parameters demand strict impurity controls, and compliance with environmental and workplace safety regulations is rigorously enforced throughout the production chain.

Industry compliance standards

• EU Regulation No 1107/2009 for authorisation of plant protection products
• China GB/T 31268–2014 (Safety for chemical pesticide production)
• ISO 9001:2015 for QC throughout agrochemical synthesis
• OECD guidelines for testing and environmental risk assessment

Typical usage ratio

• Conversion rates at 1.0–1.1 molar equivalents versus target active structure, adjusted based on yield optimization in multi-step processes
• Monitoring ensures full conversion with less than 0.2% unreacted precursor in final API

Downstream process integration

• Charged into high-pressure hydrogenation reactors or alkylation units during initial synthesis segments
• Reaction intermediates further transformed via nitrilation, amidation, or hydrolysis
• Agrochemical actives isolated through solvent extraction, crystallization, and final formulation blending

Final product types

• Herbicide technical concentrates
• Bioactive pesticide intermediates supplied to toll formulators
• Precursor compounds for crop protection formulations (water-dispersible granules, ECs, SCs)